Skip to main content
SpringerLink
Log in

Maligne Tumoren des Ovars

  • Chapter
Book cover Therapiekonzepte Onkologie

  • 55 Accesses

Zusammenfassung

Alle ovariellen Zelltypen können proleferieren oder entarten und benigne, intermediäre („borderline“) oder maligne Neoplasien hervorrufen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arian-Schad KS, Kapp DS, Hackl A, Juettner FM, Leitner H, Porsch G, LahousenM, Pickel H (1990) Radiation therapy in stage III ovarian cancer following surgery and chemotherapy. Prognostic factors, patterns of relapse, and toxicity: A preliminary report Gynecol Oncol 39: 47–55

    CAS  Google Scholar 

  2. Barakat RR, Rubin SC, Wong G, Saigo PE, Markman M, Hoskins WJ (1992) Mixed mesodermal tumor of the ovary: Analsis of prognostic factors in 31 cases. Obstet Gynecol 80: 660–664

    PubMed  CAS  Google Scholar 

  3. Berek JS (1992) Second-look versus-second-nature. Gynecol Oncol 44: –2

    Google Scholar 

  4. Berek JS, Welander C, Schink JC, Grossberg H, Montz FJ, Ziegelboim J (1991) A phase I—II trial of intraperitoneal cisplatin and alfa-interferon in patients with persistent epithelial ovarian cancer. Gynecol Oncol 40: 237–243

    Article  PubMed  CAS  Google Scholar 

  5. Bertelsen K, Jakobsen A, Stroyer I, Nielsen K, Sandberg E, Andersen JE, Ahrons S, Nyland M, Hjortkjaer Pedersen P, Larsen G, Rasmussen P, Kiaer H, Bichel P, Jacobsen M, Holund B (1993) A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer. A danish ovarian study group trial (DACOVA). Gynecol Oncol 49: 30–36

    Article  PubMed  CAS  Google Scholar 

  6. Bolis G, Zanaboni F, Vanoli P, Russo A, Franchi M, Scarfone G, Pecorelli S (1990) The impact of whole-abdomen radiotherapy on survival ovarian cancer patients with minimal residual disease after chemotherapy. Gynecol Oncol 39: 150–154

    Article  PubMed  CAS  Google Scholar 

  7. Brand E, Lidor Y (1993) The decline of CA 125 level after surgery reflects the size of residual ovarian cancer. Obstet Gynecol 81: 29–32

    PubMed  CAS  Google Scholar 

  8. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H (1991) Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 40: 103–106

    Article  PubMed  CAS  Google Scholar 

  9. Casey MJ, Gupta NC, Muths CK (1994) Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 53: 331–338

    Article  PubMed  CAS  Google Scholar 

  10. Conte PF, Bruzzone M, Chiara S, Sertoli MR, Daga MG, Rubagotti A, Conio A, Ruvolo M, Rosso R, Santi L, Carnino F, Cottini M, Mossetti C, Guercio E, Gatti M, Siliquini PN, Prelato ML, Durando C, Giaccone G, Calciati A, Farinini D, Centonze M, Rugiati S, Parodi G, Messineo M, Storace A, Bernardine G, Misurale F, Alessandri S, Casini M, Ragni N, Foglia G, Bentivoglio G, Pescetto G (1986) A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 4: 965–971

    PubMed  CAS  Google Scholar 

  11. Creasman ET, Omura GA, Brady MF, Yordan E, DiSaia PJ, Beecham J (1990) A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without Bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer. A Gynecologic Oncology Group Study. Gynecol Oncol 39: 239–243

    Article  PubMed  CAS  Google Scholar 

  12. DePalo G, Pilotti S, Kenda R et al. (1982) Natural history of dysgerminoma. Am J Obstet Gynecol 143: 799–805

    CAS  Google Scholar 

  13. Decker DG, Fleming TR, Malkasian GD, Webb MJ, Jefferies JA, Edmonson JH (1982) Cyclophosphamide plus cis-platinum in combination: Treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol 60 (4): 481–487

    Google Scholar 

  14. Dembo AJ, Bush RS, Beale FA, Bean HA, Pringle JF, Sturgeon J, Reid JG (1979) Ovarian carcinoma: Improved survival following abdominopelvic irradiation in patients with a completed pelvic operation. Am J Obstet Gynecol 134 (7): 793–800

    PubMed  CAS  Google Scholar 

  15. DiSaia PJ, Creasman WT (1993) Germ cell, stromal, and other ovarian tumors. In: PJ DiSaia, WT Creasman (eds), Clinical Gynecologic Oncology, pp 426–457, St Louis: Mosby Year Book

    Google Scholar 

  16. Donehower RC, Rowinsky EK (1993) Anticancer Drugs Derived From Plants. In: VT DeVita, S Hellman, SA Rosenberg (eds), Cancer — Principles and Practice on Oncology, J.B. Lippincott Co, Philadelphia, pp 409–417

    Google Scholar 

  17. Dufour P, Bergerat JP, Barats JC, Giron C, Duclos B, Dellenbach P, Ritter J, Renaud R, Audhuy B, Oberling F (1994) Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer 73: 1865–1869

    CAS  Google Scholar 

  18. Einhorn N, Cantell K, Einhorn S, Strander H (1982) Human leukocyte interferon therapy for advanced ovarian carcinoma: J Clin Oncol 5: 167–172

    Article  CAS  Google Scholar 

  19. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Hölzel F, Schulz KD, Schally AV (1993) High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53: 5439–5446

    PubMed  CAS  Google Scholar 

  20. Emons G, Ortmann O, Schulz KD (1994) Rolle der endokrinen Therapie beim Ovarialkarzinom Gynaekol Prax 18: 63–70

    Google Scholar 

  21. Fanning J, Bennett TZ, Hilger RD (1992) Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 80: 954–960

    PubMed  CAS  Google Scholar 

  22. Ferrier AJ, De Petrillo AD (1992) Second-look laparotomy in the routine mange-ment of ovarian cancer. In: Sharp F, Mason WP, Creasman WT (eds), Ovarian Cancer 2 — Biology, diagnosis and management, Chapman & Hall Medical, London, pp 385–394

    Google Scholar 

  23. Fiorentino MV, Nicoletto MO, Tumolo S, Puccetti C, Chiesa G, Mainini F, Nascimben O, Vinante O, Michielon E, Cima G, Rosabian A, Prosperi A, Endrizzi L, Brigato G (1994) Uselessness of surgical second look (sl) in epithelial ovarian cancer: A randomized study. Proc Annu Meet Am Soc Clin Oncol 13: 259 (Abstract)

    Google Scholar 

  24. Fishman A, Kudelka AP, Edwards CL, Freedman RS, Tresukosol D, Kaplan A, Girtanner R, Kavanagh JJ (1994) GnRH agonist (Lupron Depot) in the treatment of refractory or persistent ovarian granulosa cell tumor (GCT). Proc Annu Meet Am Soc Clin Oncol 13: 236 (Abstract)

    Google Scholar 

  25. Fishman DA, Schwartz PE (1994) Current approaches to diagnosis and treatment of ovarian germ cell malignancies. Curr Opinion Obstet Gynecol 6: 98–104

    CAS  Google Scholar 

  26. Franchin G, Tumolo S, Scarabelli C, DePaoli A, Boz G, Crivellair D, Arcicasa M, Bortolus R, Gobitti C, Minatel E, Roncardin M, Trovo MG (1991) Whole abdomen radiation therapy after a short chemotherapy course and second-lood laparotomy in advanced ovarian cancer. Obstet Gynecol 41: 206–211

    CAS  Google Scholar 

  27. Francis P, Hakes T, Schneider J, Spriggs D, Fennelly D, Hann L, Barakat RR, Curtin J, Jones W, Lewis JL Jr, Phillips M, Hoskins W (1994) Phase II study of docetaxel (Taxotere) in advanced platinum-refractory ovarian cancer. Proc Annu Meet Am Soc Clin Oncol 13: 260 (Abstract)

    Google Scholar 

  28. Frasci G, Contino A, Iaffaioli RV, Mastrantonio P, Conforti S, Persico G (1994) Computerized tomography of the abdomen and pelvis with peritoneal administration of sluble contrast (IPC-CT) in detection of residual disease for patients with ovarian cancer. Gynecol Oncol 52: 154–160

    Article  PubMed  CAS  Google Scholar 

  29. Freedman RS, Gutterman JU, Wharton JT, Rutledge FN (1983) Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma. J Biol Response Modif 2: 133–138

    CAS  Google Scholar 

  30. Gall S, Bundy B, Beecham J, Wilson H, Noburu O, Hilgers RD, O’Toole R, Thigpen JT (1986) Therapy of stage III (optimal) epithelial carcinoma of the vary with melphalan or melphalan plus Corynebacterium parvum. Gynecol Oncol 25: 26–36

    Article  PubMed  CAS  Google Scholar 

  31. Gallion HH, van Nagell JR, Donaldson ES, Higgins RV, Powell DE, Kryscio RJ (1989) Adjuvant oral alkylating chemotherapy in patients with stage I epithelial ovarian cancer. Cancer 63: 1070–1073

    Article  PubMed  CAS  Google Scholar 

  32. Gershenson DM, Burke TW, Levenback C, Warner D, Matthews C (1994) Treatment of poor prognosis sex cord stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Proc Annu Meet Am Soc Clin Oncol 13: 262 (Abstract)

    Google Scholar 

  33. Gershenson DM, Mitchell MF, Atkinson N, Silva EG, Kavanagh JJ, Morris M, Burke TW, Warner D, Wharton JT (1992) The effect of prolonged cisplatin — based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: „Maintenance“ therapy reconsidered Gynecol Oncol 47: 7–13

    CAS  Google Scholar 

  34. GICOG (1987) Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide /doxorubicin/cisplatin in advanced ovarian cancer. Lancet: 353–359

    Google Scholar 

  35. Greco FA, Julian CG, Richardson RL, Burnett L, Hande KR, Oldham RK (1981) Advanced ovarian cancer: Brief intensive combination chemotherapy and second-look operation. Obstet Gynecol 58: 199–205

    PubMed  CAS  Google Scholar 

  36. Green JA, Slater AJ (1989) A study of cis-platinum and ifosfamide in alkylating agentresistant ovarian cancer. Gynecol Oncol 32: 233–235

    Article  PubMed  CAS  Google Scholar 

  37. Guidozzi F, Ball JHS (1994) Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 53: 326–330

    Article  PubMed  CAS  Google Scholar 

  38. Hacker NF, Berek JS, Preforious G et al. (1987) Intraperitoneal cisplatin as salvage therapy for refractory epithelial ovarian cancer. Obstet Gynecol 70:759–764 38a.Hacker NF, van der Burg MEL (1993) Debulking and intervention surgery. Ann Oncol 4 (Suppl 4): S 17 –S 22

    Google Scholar 

  39. Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC, Chapman D, Almadrones L, Lewis JL Jr (1992) Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 45: 284–289

    Article  PubMed  CAS  Google Scholar 

  40. Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer MJ (1992) A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 80: 708–714

    PubMed  CAS  Google Scholar 

  41. Harlow BL, Cramer DW, Bell DA, Welch WR (1992) Perinea) exposure to talc and ovarian cancer risk. Obstet Gynecol 80: 19–26

    PubMed  CAS  Google Scholar 

  42. Hunter RW, Alexander NDE, Soutter WP (1992) Meta-analysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery an independent determinant of prognosis ? Am J Obstet Gynecol 166 (2): 504–511

    PubMed  CAS  Google Scholar 

  43. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT (1991) Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 42: 146–150

    Article  PubMed  CAS  Google Scholar 

  44. Jekunen A, Heikkilä P, Maiche A, Pyrhönen S (1994) Paclitaxel-induced myocardial damage detected by electron microscopy. Lancet 343: 727–728

    Article  PubMed  CAS  Google Scholar 

  45. Jekunen AP, Christen RD, Shalinski DR, Howell SB (1994) Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69: 299–306

    Article  PubMed  CAS  Google Scholar 

  46. Klaassen D, Shelley W, Starreveld A, Kirk M, Boyes D, Gerulath A, Levitt M, Fraser R, Carmichael J, Methot Y, Willan A (1988) Early stage ovarian cancer: A randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: A National Cancer Institute of Canada Clinical Trials Group report. J Clin Oncol 6: 1254–1263

    PubMed  CAS  Google Scholar 

  47. Ledermann JA, Dembo AJ, Sturgeon JFG, Fine S, Bush RS, Fyles AW, Pringle JF, Rawlings GA, Thomas GM, Simm J (1991) Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiation. Gynecol Oncol 41: 30–35

    Article  PubMed  CAS  Google Scholar 

  48. Lentz SS, Cha SS, Wieand HS, Podratz KC (1991) Stage I ovarian epithelial carcinoma: Survival analysis following definitive treatment. Gynecol Oncol 43: 198–202

    Article  PubMed  CAS  Google Scholar 

  49. Los G, Mutsaers PHA, Lenglet WJM et al. (1990) Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 25: 389–394

    Article  PubMed  CAS  Google Scholar 

  50. Louie KG, Ozols RF, Myers CE, Ostchega Y, Jenkins J, Howser D, Young RC (1986) Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J Clin Oncol 4: 1579–1585

    PubMed  CAS  Google Scholar 

  51. Lund B, Hansen M, Handen OP, Hansen HH (1989) High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 7: 1469–1473

    PubMed  CAS  Google Scholar 

  52. Mallmann P, Krebs D (1994) Aktuelle Zytokintherapie in der gynäkologischen Onkologie. Gynaecol Prax 18: 323–330

    Google Scholar 

  53. Malmström H, Simonsen E, Westberg R (1994) A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients. Gynecol Oncol 52: 20–25

    Article  PubMed  Google Scholar 

  54. Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G, Gambino A, Landoni F, Presti M, Torri W, Vassena L, Zanaboni F, Marsoni S, (1989) Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst, 81: 1464–1471

    Article  PubMed  CAS  Google Scholar 

  55. Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homesley HD (1992) Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy. Lessons learned from a Gynecologie Oncology Group phase II trial of ip cisplatin and recombinant alfa-interferon. Gynecol Oncol 45: 3–8

    Article  PubMed  CAS  Google Scholar 

  56. Markman M, Reichman B, Hakes T, Rubin S, Jones W, Lewis JL Jr, Barakat RR, Curtin JP, Almadrones L, Hoskins W (1992) Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer. Gynecol Oncol 47: 353–357

    Article  PubMed  CAS  Google Scholar 

  57. Marth C, Mull R, Gastl G, Herold M, Steiner E, Daxenbichler G, Hetzel H, Flener R, Huber C, Dapunt O (1989) Die intraperitoneale Instillation von Interferon-gamma zur Behandlung des refraktären Ovarialkarzinoms. Geburtsh u Frauenheilk 49: 987–991

    Article  CAS  Google Scholar 

  58. Masding J, Sarkar TK, White WF, Barley VL, Chawla SL, Boesen E, Rostom AY, Menday AP (1990) Intravenous treosulfan versus intravenous trosulfan plus ciplatinum in advanced ovarian carcinoma. Br J Obstet Gynecol 97: 342–351

    Article  CAS  Google Scholar 

  59. McGuire WP, Rowinsky EK, Rosenshein NB et al. (1989) Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273–279

    Article  PubMed  CAS  Google Scholar 

  60. Miller DS, Spirtos NM, Ballon SC, Cox RS, Soriero OM, Teng NNH (1992) Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Cancer 69: 502–510

    Article  PubMed  CAS  Google Scholar 

  61. Moore DH, Valea F, Crumpler LS, Fowler WC Jr (1993) Hexamethylmelamine/Altretamine as second-line therapy for epithelial ovarian carcinoma. Gynecol Oncol 51: 109–112

    Article  PubMed  CAS  Google Scholar 

  62. Neijt JP (1991) Ovarian cancer treatment. Time for some hard thinking. Eur J Cancer 27 (6): 680–681

    Article  PubMed  CAS  Google Scholar 

  63. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, van Oosterom AT, Willem-se PHB, Heintz APM, van Lent M, Rimbos JB, Bouma J, Vermorken JB, van Houwelingen JC (1987) Randomized trial comparing two combination chemotherapy regimens (CHAP-5 CP) in advanced ovarian carcinoma. J Clin Oncol 5: 1157–1168

    PubMed  CAS  Google Scholar 

  64. Nichols CR, Tricot G, Williams SD et al. (1989) Dose-intensive chemotherapy in refractory germ cell cancer: A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7: 932–937

    PubMed  CAS  Google Scholar 

  65. Norris HJ, Zirkin HJ, Benson WL (1976) Immature (malignant) teratoma of the ovary: A clinical and pathologic study of 58 Cases. Cancer 37: 2359–2365

    Article  PubMed  CAS  Google Scholar 

  66. Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, Homesley HD (1986) A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer 57:1725 –1730

    Google Scholar 

  67. Ozols RF, Ostchega Y, Curt G, Young RC (1987) High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 5: 197–201

    PubMed  CAS  Google Scholar 

  68. Ozols RF, Rubin SC, Dembo AJ, Robboy S (1992) Epithelial Ovarian Cancer. In: Hoskins WJ, Perez, CA, Young RC (eds), Principles and Practice of Gynecologic Oncology, J.B. Lippincott Co, Philadelphia, pp 731–781

    Google Scholar 

  69. Parazzinie F, Franceschi S, La Vecchia C, Fasoli M (1991) The epidemiology of ovarian cancer. Gynecol Oncol 43: 9–23

    Article  Google Scholar 

  70. Petru E, Lohousen M, Tamussion K, Pickel H, Stranzl H, Stettner H, Winter R (1994) Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol 170: 656–662

    PubMed  CAS  Google Scholar 

  71. Pfleiderer A (1989) Malignome des Ovars. In: Wulf KH, Schmidt-Matthiesen H (eds), Klinik der Frauenheilkunde and Geburtshilfe — Spezielle gynäkologische Onkologie II, Urban & Schwarzenberg Verlag, München Wien Baltimore, pp 45–129

    Google Scholar 

  72. Piver MS, Malfetano J, Baker TR, Hempling RE (1992) Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin — based chemotherapy. Gynecol Oncol 46: 357–360

    Article  PubMed  CAS  Google Scholar 

  73. Piver MS, Recio FO, Baker TR, Driscoll D (1994) Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer. Cancer 73: 1693–1698

    Article  PubMed  CAS  Google Scholar 

  74. Potter ME, Hatch KD, Soong SJ, Partridge EE, Austin JM, Shingleton HM (1992) Second-look laparotomy and salvage therapy: A research modality only? Gynecol Oncol 44: 3–9

    Article  PubMed  CAS  Google Scholar 

  75. Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM, Shingleton HM (1991) Primary surgical therapy of ovarian cancer: How much and when. Gynecol Oncol 40: 195–200

    Article  PubMed  CAS  Google Scholar 

  76. Repetto L, Chiara S, Mammoliti S, Guido T, Bruzzone M, Secondo V, Donadio G, Odicino F, Ragni N, Conte PF, Rosso P (1990) Crossover study with cisplatin or carboplatin and advanced ovarian cancer. Gynecol Oncol 39: 146–149

    Article  PubMed  CAS  Google Scholar 

  77. Rubin SC, Finstad CL, Federici MG, Scheiner L, Lloyd KO, Hoskins WJ (1994) Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 73: 1456–1459

    Article  PubMed  CAS  Google Scholar 

  78. Rubin SC, Wong GYC, Curtin JP, Barakat RR, Hakes TB, Hoskins WJ (1993) Platinum-based chemotherapy of high-risk stage I ovarian cancer following comprehensive surgical staging. Obstet Gynecol 82: 143–147

    PubMed  CAS  Google Scholar 

  79. Sell A, Bertelsen K, Andersen JE, Stroyer I, Panduro J (1990) Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. Gynecol Oncol 37: 367–373

    Article  PubMed  CAS  Google Scholar 

  80. Sevelda P, Mayerhofer K, Obermair A, Stolzlechner J, Kurz C (1994) Thrombosis with paclitaxel. Lancet 343: 727

    Article  PubMed  CAS  Google Scholar 

  81. Seymour MT, Mansi IL, Gallagher CJ, Gore ME, Harper PG, Evans TRJ, Edmonds PM, Selvin ML (1994) Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 69: 191–195

    Article  PubMed  CAS  Google Scholar 

  82. Singleton TP, Perrone T, Oakley G, Niehans GA, Carson L, Cha SS, Strickler JG (1994) Activation of c-erbB-2 and prognosis in ovarian carcinoma. Cancer 73: 1460–1466

    Article  PubMed  CAS  Google Scholar 

  83. Stewart LA, AOCTG (1991) Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials. Br Med J 303: 884–893

    Google Scholar 

  84. Sutton G (1993) Ifosfamide and mesna in epithelial ovarian carcinoma. Gynecol Oncol 51: 104–108

    Article  PubMed  CAS  Google Scholar 

  85. Sutton GP, Blessing JA, Homesley HD et al. (1989) Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 7: 1672–1676

    PubMed  CAS  Google Scholar 

  86. Sutton GP, Stehman FB, Einhorn LH, Roth LM, Blessing JA, Ehrlich CE (1989) Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 7: 223–229

    PubMed  CAS  Google Scholar 

  87. Tattersall MHN, Swanson CE, Solomon HJ (1992) Long-term survival with advanced ovarian cancer: An analysis of 5-year survivors in the Australian Trial comparing combination versus sequential chlorambucil and cisplatin therapy. Gynecol Oncol 47: 292–297

    Article  PubMed  CAS  Google Scholar 

  88. ten Bokkel Huinink WW, Dubbleman R, Aarsten E et al. (1985) Experimental and clinical results with intraperitoneal cisplatin. Semin Oncol 12 (3S): 43–55

    Google Scholar 

  89. Thomas GM (1993) Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer? Gynecol Oncol 51: 97–103

    Article  PubMed  CAS  Google Scholar 

  90. van der Burg MEL, van Lent M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Buyse M, Pecorelli S (1993) Proc Annu Meet Am Soc Clin Oncol 12: 818 (Abstract)

    Google Scholar 

  91. Vergote I, Himmelmann A, Frankendal B, Scheiströen M, Vlachos K, Trope C (1992) Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol 47: 282–286

    Article  PubMed  CAS  Google Scholar 

  92. Vergote IB, Vergote-De Vos L, Abeler VM, Aas M, Lindegaard MW, Kjorstad KE, Trope CG (1992) Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 69: 741–749

    Article  PubMed  CAS  Google Scholar 

  93. la. Vermorken JB, ten Bokkel Huinink WW, Eisenhauer EA, Favalli G, Belpomme D, Conte PF, Kaye SB (1993) Carboplatin versus Cisplatin. Ann Oncol 4 (Suppl 4): S41–S48

    Article  Google Scholar 

  94. Walton LA, Yadusky A, Rubinstein L, Roth LM, Young RC (1992) Stage II carcinoma of the ovary: An analysis of survival after comprehensive surgical staging and adjuvant therapy. Gynecol Oncol 44: 55–60

    Article  PubMed  CAS  Google Scholar 

  95. Whittemore AS, Wu ML, Paffenbarger RS Jr, Sarles DL, Kampert JB, Grosser S, Jung DL, Ballon S, Hendrickson M, Mohle-Boetani J (1989) Epithelial ovarian cancer and the ability to conceive. Cancer Res 49 (14): 4047–4052

    PubMed  CAS  Google Scholar 

  96. Willemse PHB, Aalders JG, Bouma J, Mulder NH, Verschueren RCJ, de Vries EGE, Sleijfer DT (1987) Long-term survival after vinblastine, bleomycin, and cisplatin treatment with germ cell tumors of the ovary: An update. Gynecol Oncol 28: 268–177

    Article  PubMed  CAS  Google Scholar 

  97. Williams SD, Birch R, Einhorn LH et al. (1987) Disseminated germ cell tumors: Chemotherapy with cisplatin plus bleomycin plus either vinblastine or etoposide. N Engl J Med 316: 1435–1440

    Article  PubMed  CAS  Google Scholar 

  98. Wiliams SD, Blessing JA, DiSaia PJ, Major FJ, Ball HG III, Liao SY (1994) Second-look laparotomy in ovarian germ cell tumors: The Gynecologic Oncology Group Experience. Gynecol Oncol 52: 287–291

    Article  Google Scholar 

  99. Williams SD, Blessing JA, Moore DH et al. (1989) Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. Ann Intern Med 111: 22–27

    Article  PubMed  CAS  Google Scholar 

  100. Williams SD, Gershenson DM, Horowith CJ, Scully RE (1992) Ovarian Germ Cell and Stromal Tumors. In: Hoskins WJ, Perez CA, Young RC (eds), Principles and Practice of Gynecologic Oncology, J.B. Lippincott Co, Philadelphia, pp 715–730

    Google Scholar 

  101. Wong LC, Collins RJ, Ngan HYS, Ma HK (1990) Etoposide combination chemotherapy in refractory ovarian malignant germ cell tumor. Gynecol Oncol 39: 123–126

    Article  PubMed  CAS  Google Scholar 

  102. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F Jr (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer. N Engl J Med 322: 1021–1027

    Article  PubMed  CAS  Google Scholar 

  103. Zanaboni F, Scarfone G, Presti M, Maggi R, Borello C, Bolis G (1991) Salvage chemotherapy for ovarian cancer recurrence: Weekly cisplatin in combination with epirubicin or etoposide. Gynecol Oncol 43: 24–28

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. G. Bastert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. D. Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung) Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Bastert, G., Costa, S.D. (1995). Maligne Tumoren des Ovars. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10494-1_46

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10494-1_46

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-58586-2

  • Online ISBN: 978-3-662-10494-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation